cognitive cybersecurity intelligence

News and Analysis


The race for RSV vaccine development and approval in 2023

AstraZeneca has boosted its presence in the race to develop a vaccine for respiratory syncytial virus (RSV), via a $1.1bn deal with American company Icosavax. The agreement means AstraZeneca, which is also the co-developer of the RSV-specific antibody Beyfortus, will gain access to Icosavax’s RSV vaccine candidate. The U.K. multinational’s move comes after GSK’s Arexvy became the first-ever RSV vaccine to go to market, approved by the FDA, followed shortly by Pfizer’s own vaccine.

Source: –

Subscribe to newsletter

Subscribe to HEAL Security Dispatch for the latest healthcare cybersecurity news and analysis.

More Posts